MediNet Group (HKSE:08161) Research & Development: HK$0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:08161 MediNet Group Ltd HKSE:08161
43 GF Score
Price HK$0.66
GF Value HK$0.29
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is MediNet Group Research & Development?

MediNet Group HKSE:08161 43 Research & Development is HK$0.00 Mil as of Mar. 2026. GuruFocus rates HKSE:08161 with a GF Score™ of 43/100 and a GF Value™ of HK$0.29 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. MediNet Group's Research & Development for the six months ended in Mar. 2026 was HK$0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was HK$0.00 Mil.

MediNet Group  (HKSE:08161) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

MediNet Group Research & Development Related Terms

MediNet Group Research & Development Historical Data

* Premium members only.

The historical data trend for MediNet Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MediNet Group Research & Development Chart

MediNet Group Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MediNet Group Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HKSE:08161
43GF Score
MediNet Group Ltd HKSE:08161
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MediNet Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$0.00 Mil mean?
MediNet Group (HKSE:08161) has a Research & Development of HK$0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on MediNet Group and its competitors.
Is MediNet Group's Research & Development too high?
MediNet Group's current Research & Development is HK$0.00 Mil. Overall, MediNet Group has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MediNet Group's Research & Development compare to HCA and THC?
MediNet Group's Research & Development of HK$0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on MediNet Group and its competitors. MediNet Group's current Research & Development is HK$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediNet Group stock overvalued right now?
Based on GuruFocus' analysis, MediNet Group (HKSE:08161) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.29, compared to a current price of HK$0.66 — trading 127.6% above its estimated fair value. The current Research & Development is HK$0.00 Mil. MediNet Group's overall GF Score™ is 43/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For MediNet Group (HKSE:08161), the current Research & Development is HK$0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MediNet Group (HKSE:08161) Overvalued in 2026?

Based on GuruFocus' analysis, MediNet Group stock appears to be overvalued. The current stock price of HK$0.66 is trading 127.6% above its estimated GF Value™ of HK$0.29. GuruFocus considers MediNet Group to be Significantly Overvalued.

Key valuation signals for HKSE:08161:

  • Research & Development: HK$0.00 Mil
  • GF Value™: HK$0.29 vs. price of HK$0.66 (127.6% above fair value)
  • GF Score™: 43/100 with 7 warning signs

No single metric tells the full story. See the HKSE:08161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MediNet Group Business Description

Address 18 Whitfield Road, Causeway Bay, Unit 3601, 36th Floor, Citicorp Centre, Hong Kong, HKG
MediNet Group Ltd is a provider of corporate healthcare solutions in Hong Kong. The company's operating segment includes the Dental business and the Medical business. The Dental segment offers dental solutions and dental services by dental clinics owned and operated by the group. Its Medical segment provides outpatient general services and men's health treatment services. It offers services to both plan members and self-paid patients. Geographically, the company generates the majority of its revenue from Hong Kong.
43GF Score

Get the complete analysis for HKSE:08161

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.66
Price
HK$0.29
GF Value